SumantaK.PalMD

PubMed

• Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma.
  Justine Panian, Caiwei Zhong, Sharon H Choi, Kristine Ly, Roxanne Quinn
  European Urology Focus. 2024-12-07
• Exercising and immuno-oncology treatment (ExIO): a prospective pilot study for patients with solid tumors.
  Paulo Gustavo Bergerot, Cristiane Decat Bergerot, Jonas Ribeiro Gomes Silva, William Hiromi Fuzita, Marcos V S Franca
  Supportive Care in Cancer. 2024-12-02
• 2 citations
  Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010.
  Jose Antonio Karam, Robert Uzzo, Axel Bex, William Leung, Connie Tat
  European Urology Oncology. 2024-12-01

Journal Articles

• Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...  
  Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
• Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma  
  Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
• STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers  
  Sumanta Pal, MD, Clinical Cancer Research
• Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis  
  Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ, Clin Genitourin Cancer, 1/1/2017
• Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular en...  
  Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenehjem DD, Agarwal N, J Oncol Pharm Pract, 1/1/2017
• Characterizing the outcomes of metastatic papillary renal cell carcinoma  
  Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishamp..., Cancer Med, 1/1/2017
• Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinom...  
  Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N, Oncotarget, 1/1/2017
• Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment  
  Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, Chang SL, Trinh QD, Choueiri TK, Eur Urol, 1/1/2017
• Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective Internat...  
  Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury..., Eur Urol, 1/1/2017
• Biomarkers in Genitourinary Cancers: Blazing the Path Forward  
  Pal SK, Karam JA, Chennamsetty A, Jones JO, Eur Urol, 1/1/2017
• Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?  
  Pal SK, Maia MC, Dizman N, Agarwal N, Eur Urol, 1/1/2017
• Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA  
  Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ, Int J Urol, 1/1/2017
• Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma  
  Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK, Eur Urol,, 1/1/2017
• Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial  
  Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishna..., Lancet Oncol, 1/1/2017
• Vitamin K epoxide reductase regulation of androgen receptor activity  
  Tew BY, Hong TB, Otto-Duessel M, Elix C, Castro E, He M, Wu X, Pal SK, Kalkum M, Jones JO, Oncotarget, 1/1/2017
• Vitamin K epoxide reductase expression and prostate cancer risk  
  Tew BY, Pal SK, He M, Tong T, Wu H, Hsu J, Liu X, Neuhausen SL, Jones JO, Urol Oncol, 1/1/2017
• Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium  
  Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A..., Eur Urol, 1/1/2017
• Genomic mutation-driven metastatic breast cancer therapy: a single center experience  
  Yuan Y, Yost SE, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J, Oncotarget, 1/1/2017
• Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine  
  Agarwal N, Sonpavde G, Choueiri TK, Pal SK, Eur Urol, 1/1/2016
• Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer  
  Rose TL, Deal AM, Ladoire S, Crehange G, Galsky MD, Rosenberg JE, Bellmunt J, Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK,..., Bladder Cancer, 1/1/2016
• Developing a Clear Path Forward for Non-Clear-Cell Renal Carcinoma  
  Pal SK, Karam JA, Bergerot P, Agarwal N, J Clin Oncol, 1/1/2016
• Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar  
  Pal SK, Agarwal N, Dizman N, Sonpavde G, Lancet Oncol, 1/1/2016
• Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations  
  Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA, Eur Urol, 1/1/2016
• Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study  
  Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD, Choueiri TK, J Clin Oncol, 1/1/2016
• Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial  
  Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg C..., Lancet Oncol, 1/1/2016
• Join now to see all

Books/Book Chapters

• Renal Cell Carcinoma: Biology, Prognostic Factors and Therapeutic Targets 
  Chapter: Characterizing and Modulating the Tumor Micro-Environment in Renal Cell Carcinoma: Potential Therapeutic Strategies 
  Pal SK, Reckamp K, Yu H, Figlin RAEditors: Figlin RA, Rathmell WK, Rini B.Springer Publishing Company, New York, NY2012
• Kidney Cancer – Principles and Practice 
  Chapter: Emerging agents in renal cell carcinoma 
  Pal SK, Josephson DY, Twardowski P, Quinn DIEditors: Lara P, Jonasch E.Lippincott & Wilkins, Philadelphia, PA2010
• Comprehensive Textbook of Genitourinary Oncology 
  Chapter: Immunotherapy in the management of renal cell carcinoma 
  Pal SK, Reckamp KL, Yu H, Figlin RAEditors: Vogelzang N.Lippincott & Wilkins, Philadelphia, PA2010
• A multidisciplinary approach to lung cancer 
  Chapter: Targeted pathways in NSCLC and SCLC 
  Pal SK, Reckamp KLEditors: Kernstine K.Demos Medical Publishers, New York, NY2010
• A multidisciplinary approach to lung cancer 
  Chapter: Lung Cancer in Older Adults 
  Pal SK, Hurria AEditors: Kernstine K.Demos Medical Publishers, New York, NY2010
• Diseases of the Breast 
  Chapter: Treatment of HER2-Overexpressing Metastatic Breast Cancer 
  Pal SK, Pegram MEditors: Harris JN.Lippincott-Raven, Philadelphia, PAEdition 4th,2009
• Management of Breast Cancer in the Older Adult 
  Chapter: Adjuvant Chemotherapy 
  Pal SK, Vora N, Hurria AEditors: Reed M.Springer2008
• Cancer 
  Chapter: Trends in molecularly targeted therapies for renal cell carcinoma 
  Pal SK, Figlin RAEditors: Schwab M.Springer2008
• New Treatment Paradigms in Renal Cell Cancer 
  Chapter: Prognostic Factors in Renal Cell Carcinoma Patients: Localized and Metastatic Disease 
  Pal SK, Figlin RAEditors: Bukowski R.CMP Medica, Manhasset, NY2007
• Join now to see all

Abstracts/Posters

• Comprehensive genomic profiling of urothelial carcinoma of the kidney and ureter: Comparison with urothelial carcinoma of the bladder and impact on potential for targe...
  Pal SK, Elvin JA, Ali SM, Hoffman-Censits JH, Vergilio J-A, Suh J, Mian B, Fisher HAG, Nazeer T, Miller VA, Stephens PJ, Ross JS, ASCO Meeting, 1/1/2016
• Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma of the bladder
  Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz A, Sonpavde G, 1/1/2016
• AR DNA binding domain inhibitors to treat AR splice variant-driven prostate cancer
  Jones J, otto-Duessel M, Zhou Y, Pal SK, 1/1/2016
• Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma
  Ho TH, Choueiri TK, Wang K, Karam JA, Chalmers ZR, Frampton GM, Elvin JA, Johnson A, Liu X, Lin Y, Joseph RW, Stanton ML, Miller VA, Stephens PJ, Ross JS, Ali SM, Pal SK, 1/1/2016
• Prospective front-line management patterns in the Real World Metastatic Renal Cell Cancer (MaRCC) Registry
  Harrison MR, Bhavsar NA, Wolf SP, Costello BA, Vaishampayan UN, Kyriakopoulos C, Stadler WM, Hammers HJ, Appleman LJ, Tsao C-K, Pal SK, Hussain A, Jim HSL, Borham A, G..., ASCO Meeting Abstracts, 1/1/2016
• Deferred systemic therapy (DST) in the prospective metastatic renal cell cancer (MaRCC) registry
  Harrison MR, Bhavsar NA, Wolf SP, Costello BA, Vaishampayan UN, Kyriakopoulos C, Stadler WM, Hammers HJ, Appleman LJ, Tsao C-K, Pal SK, Hussain A, Jim HSL, Borham A, G..., 1/1/2016
• Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate
  Pal SK, Milowsky MI, Elvin JA, Ali SM, Hoffman-Censits JH, Vergilio J-A, Suh J, Mian B, Fisher HAG, Nazeer T, Miller VA, Stephens PJ, Ross JS, 1/1/2016
• Understanding the mechanism of warfarin-mediated PC prevention
  Jones J, Tew BY, otto-Duessel M, Tong T, Kalkum M, Hong T, Liu X, Pal SK, 1/1/2016
• Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) ...
  Pal SK, Rosenberg JE, Keam B, Wolf J, Berger R, Dittrich C, Hoffman-Censits JH, Quinn D, van der Noll R, Burris HA, Galsky MD, Gravis G, Lee J-L, Medioni J, Mortazavi ..., 1/1/2016
• Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer
  Galsky MD, Hahn NM, Albany C, Fleming MT, Starodub A, Twardowski P, Pal SK, Hauke RJ, Sonpavde G, Oh WK, Bhardwaj N, Gnjatic S, Kim-Schulze S, Liu Z, 1/1/2016
• Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers
  Fay AP, Madison R, Lee RJ, Karam JA, Ross JS, Miller VA, Stephens P, Ali SM, Pal SK, Choueiri TK, 1/1/2016
• The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination ch...
  Necchi A, Sonpavde G, Lo Vullo S, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Ladoire S, Wong Y-N, Yu EY, Chowdhury S, Niegisch G, Srinivas..., 1/1/2016
• Comprehensive genomic profiling of renal cell carcinoma with sarcomatoid dedifferentiation to pinpoint recurrent genomic alterations
  Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Mouawad R, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, K..., 1/1/2016
• Correlation of genomic alterations with outcome in patients (pts) with urothelial carcinoma (UC)
  Emamekhoo H, Vasekar MK, Joshi M, Li SM, Basu A, Hsu J, Zhu J, Frampton GM, Ali SM, Miller VA, Ross JS, Rini BI, Garcia JA, Pal SK, Grivas P, 1/1/2016
• Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal c...
  Powles T, Motzer RJ, Escudier BJ, Pal SK, Kollmannsberger CK, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M, Grande E, Suarez C, Arroyo AM, Dean M, ..., 1/1/2016
• Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC)
  Dorff TB, Longmate J, Groshen SG, Stadler WM, Fishman MN, Vaishampayan UN, Pinski JK, Pal SK, Hu J, Quinn DI, Lara P, 1/1/2016
• Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa)
  Sonpavde G, Nagy RJ, Agarwal N, Gourdin TS, Naik G, Eshaghian S, Wang J, Armstrong AJ, Vaishampayan UN, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB, 1/1/2016
• Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma
  Sonpavde G, Nagy RJ, Apolo AB, Agarwal N, Pal SK, Grivas P, Vaishampayan UN, Lanman RB, Talasaz A, 1/1/2016
• Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma
  Agarwal N, Tagawa ST, Chatta GS, Pal SK, Goel S, Mazhari R, Heaton C, Benaim E, 1/1/2016
• Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate
  Stephens PJ, Gay LM, Ali SM, Hoffman-Censits JH, Elvin JA, Vergilio J-A, Suh J, Mian B, Fisher HAG, Nazeer T, Miller VA, Pal SK, Ross JS, 1/1/2016
• Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC)
  Choueiri TK, Powles T, Escudier BJ, Tannir NM, Mainwaring P, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee J-L, Heng DYC, Schmidinger M, Aftab DT, Hessel C, ..., 1/1/2016
• Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC)
  Rose TL, Ladoire S, Crehange G, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Wong Y-N, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang ..., 1/1/2016
• Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB)
  Bergerot PG, Sonpavde G, Nelson RA, Agarwal N, Costa CN, Hsu J, Choueiri TK, Pal SK, 1/1/2016
• Genomic landscape of urothelial cancer (UC), chemotherapy (CTX) response, and outcome based on smoking status
  Vasekar MK, Emamekhoo H, Grivas P, Hsu J, Li SM, Zhu J, Basu A, Drabick JJ, Holder SL, Warrick J, Kaag M, Frampton GM, Ali SM, Miller VA, Ross JS, Pal SK, Joshi M, 1/1/2016
• Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic malignancies
  Bergerot PG, Nelson RA, Ye D-W, Grivas P, Singh P, Agarwal N, Choueiri TK, Pal SK, 1/1/2016
• Join now to see all

Lectures

• Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcin... 
  2019 ASCO Annual Meeting - 6/1/2019
• Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018